SECsense Logo

Bright Minds Biosciences Inc. February 2025 Financial Report Highlights

$DRUG
Form 6-K
Filed on: 2025-02-14
Source
Bright Minds Biosciences Inc. February 2025 Financial Report Highlights

Here are the key insights extracted from the provided financial report section of Bright Minds Biosciences Inc.'s Form 6-K:

  1. Company Information:
  • Name: Bright Minds Biosciences Inc.
  • Address: 19 Vestry Street, New York, NY 10013.
  • Commission File Number: 001-40997.
  1. Filing Type:
  • This is a Form 6-K, which is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
  1. Reporting Period:
  • The report is for the month of February 2025 and includes financial data for the three months ended December 31, 2024, and December 31, 2023.
  1. Financial Documents Included:
  • The report includes:
    • Exhibit 99.1: Condensed Interim Consolidated Financial Statements.
    • Exhibit 99.2: Management's Discussion and Analysis (MD&A) for the First Quarter Ended December 31, 2024.
    • Exhibit 99.3: Certification of Interim Filings by the CEO.
    • Exhibit 99.4: Certification of Interim Filings by the CFO.
  1. Filing Incorporation:
  • The information in the Interim Financials and Interim MD&A is incorporated by reference into the company’s registration statement on Form F-3 (File No. 333-284694), originally filed on February 5, 2025.
  1. Signatory:
  • The report has been signed by Ryan Cheung, the Chief Financial Officer, on February 13, 2025.

This report indicates that Bright Minds Biosciences is providing essential updates on its financial performance and management discussion for the specified periods, which is crucial for stakeholders analyzing the company’s financial health.